The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Idraparinux versus Standard Therapy for Venous Thromboembolic Disease
Open accessAbstract
BACKGROUND: Venous thromboembolism is treated with unfractionated heparin or low-molecular-weight heparin, followed by a vitamin K antagonist. We investigated the potential use of idraparinux, a long-acting inhibitor of activated factor X, as a substitute for standard therapy. METHODS: We conducted two randomized, open-label noninferiority trials involving 2904 patients with deep-vein thrombosis and 2215 patients with pulmonary embolism to compare the efficacy and safety of idraparinux versus standard therapy. Patients received either subcutaneous idraparinux (2.5 mg once weekly) or a heparin followed by an adjusted-dose vitamin K antagonist for either 3 or 6 months. The primary efficacy outcome was the 3-month incidence of symptomatic recurrent venous thromboembolism (nonfatal or fatal). RESULTS: In the study of patients with deep venous thrombosis, the incidence of recurrence at day 92 was 2.9% in the idraparinux group as compared with 3.0% in the standard-therapy group (odds ratio, 0.98; 95% confidence interval [CI], 0.63 to 1.50), a result that satisfied the prespecified noninferiority requirement. At 6 months, the hazard ratio for idraparinux was 1.01. The rates of clinically relevant bleeding at day 92 were 4.5% in the idraparinux group and 7.0% in the standard-therapy group (P=0.004). At 6 months, bleeding rates were similar. In the study of patients with pulmonary embolism, the incidence of recurrence at day 92 was 3.4% in the idraparinux group and 1.6% in the standard-therapy group (odds ratio, 2.14; 95% CI, 1.21 to 3.78), a finding that did not meet the noninferiority requirement. CONCLUSIONS: In patients with deep venous thrombosis, once-weekly subcutaneous idraparinux for 3 or 6 months had an efficacy similar to that of heparin plus a vitamin K antagonist. However, in patients with pulmonary embolism, idraparinux was less efficacious than standard therapy. (ClinicalTrials.gov numbers, NCT00067093 [ClinicalTrials.gov] and NCT00062803 [ClinicalTrials.gov].).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antithrombotic Therapy for Venous Thromboembolic Disease
Hyers, T. M., Agnelli, G., Hull, R. D., Morris, T. A., Samama, M., Tapson, V., & Weg, J. G. (2001) · Chest · doi:10.1378/chest.119.1_suppl.176s · Cited by 2,042
Antithrombotic Therapy for Venous Thromboembolic Disease
Büller, H. R., Agnelli, G., Hull, R. D., Hyers, T. M., Prins, M. H., & Raskob, G. E. (2004) · Chest · doi:10.1378/chest.126.3_suppl.401s · Cited by 1,249
(2003) · New England Journal of Medicine · doi:10.1056/nejmoa035451 · Cited by 887
Low-Molecular-Weight Heparin in the Treatment of Patients with Venous Thromboembolism
(1997) · New England Journal of Medicine · doi:10.1056/nejm199709043371001 · Cited by 784
Büller, H. R., Davidson, B. L., Decousus, H., Gallus, A., Gent, M., Piovella, F., Prins, M. H., Raskob, G., Segers, A. E. M., Cariou, R., et al. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-11-200406010-00007 · Cited by 617
Brandjes, D. P. M., Heijboer, H., Büller, H. R., de Rijk, M., Jagt, H., & ten Cate, J. W. (1992) · New England Journal of Medicine · doi:10.1056/nejm199211193272103 · Cited by 480
van Dongen, C. J., van den Belt, A. G., Prins, M. H., & Lensing, A. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001100.pub2 · Cited by 433
Quinlan, D. J., McQuillan, A., & Eikelboom, J. W. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-3-200402030-00008 · Cited by 386
Heparin kinetics in venous thrombosis and pulmonary embolism.
Hirsh, J., van Aken, W. G., Gallus, A. S., Dollery, C. T., Cade, J. F., & Yung, W. L. (1976) · Circulation · doi:10.1161/01.cir.53.4.691 · Cited by 277
Low-Molecular-Weight Heparin in the Treatment of Patients With Venous Thromboembolism
(1998) · Journal of Urology · doi:10.1016/s0022-5347(01)63665-6 · Cited by 171
Persist investigators (2004) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2003.00516.x · Cited by 128
Heparin Pharmacokinetics: Increased Requirements in Pulmonary Embolism
Simon, T. L., Hyers, T. M., Gaston, J. P., & Harker, L. A. (1978) · British Journal of Haematology · doi:10.1111/j.1365-2141.1978.tb07133.x · Cited by 96
Tu, D. (1998) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543409808835238 · Cited by 40
Cited by
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
Antithrombotic Therapy for VTE Disease
Kearon, C., Akl, E. A., Ornelas, J., Blaivas, A., Jimenez, D., Bounameaux, H., Huisman, M., King, C. S., Morris, T. A., Sood, N., et al. (2016) · Chest · doi:10.1016/j.chest.2015.11.026 · Cited by 4,830
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Self-citationBüller (2012) · doi:10.1056/nejmoa1113572 · Cited by 2,353
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Masiukiewicz, U., Pak, R., Thompson, J., Raskob, G. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302507 · Cited by 2,324
Metadata
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-09-13
- Volume
- 357
- Issue
- 11
- Pages
- 1094-1104
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2189476799
- Cited by
- 335
- References
- 13
- FWCI
- 26.07
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.